[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
DOI:
https://doi.org/10.7175/fe.v17i1.1238Keywords:
Budget impact, Empagliflozin, SGLT-2i, DiabetesAbstract
BACKGROUND: Empagliflozin is the most recent molecule in the SGLT-2i class, new antidiabetic drugs that reduce renal glucose absorption by determining the excretion in the urine. The high prevalence of T2D, the chronicity of the condition and the severe economic and social burden caused by the disease, impose the need for a careful health economic assessment on each therapeutic innovation in this area.AIM: The aim of this study was to assess the budget impact of adopting empagliflozin in the diabetic population currently treated with sulfonylureas and potentially eligible for treatment with SGLT-2i.
METHODS: The budget impact analysis was conducted from the perspective of the Italian National Health Service over a period of three years, through an analytic model developed in MS Excel. The target population was estimated in about 170,000 patients currently treated with sulfonylureas, based on the growth forecasts of the Italian population, epidemiological estimates and drug-use information available in the literature on diabetes in Italy. In the base case was assumed a replacement rate of sulfonylureas equal to 10%, 20% and 30% respectively at the first, second and third year of analysis. A scenario analysis was considered assuming a constant uptake of 100% since the first year. The following direct healthcare costs were considered: 1) acquisition of antidiabetic drugs as the main therapy and as rescue therapy; 2) self-monitoring of blood glucose; 3) management of severe hypoglycemic events and 4) management of major cardiovascular events. Clinical effectiveness data was based on the published literature and unit costs were derived from current prices and tariffs. Oneway sensitivity analysis was developed to assess the impact of input’s uncertainty on the overall result.
RESULTS: The base case analysis presented a substantially neutral impact on the budget. The 3-year cumulative impact was -454.337 €, corresponding to a 0.1% saving. This means that the replacement of sulphonylureas with empagliflozin determines an increase in acquisition costs of drugs, which is entirely offset by the reduction in costs of self-monitoring of blood glucose, management of hypoglycemic events and cardiovascular events. The scenario analysis, based on the assumption of a full substitution of sulphonylureas with empagliflozin at the first year, yielded a more enhanced savings. The cumulative impact was -2.269.517 €, corresponding to a 0.6% saving.
CONCLUSIONS: The present study shows that the replacement of sulfonylureas (a class of generic products) with empagliflozin, motivated by the advantageous efficacy and safety profile, can take place optimizing healthcare expenditure for the management of DT2.
[In Italian]
References
Cangoz S, Chang YY, Chempakaseril SJ, et al. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors. J Clin Pharm Ther 2013; 38: 350-9; http://dx.doi.org/10.1111/jcpt.12077
Sullivan SD, Mauskopf JA, Augustovski F, et al. Principles of good practice for budget impact analysis II: Report of the ISPOR task force on good research practices – budget impact analysis. Value Health 2014: 17: 5-14; http://dx.doi.org/10.1016/j.jval.2013.08.2291
ISTAT Previsioni demografiche (2016-2018). Disponibile online su: http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PREVDEM (ultimo accesso dicembre 2015)
SID – Società Italiana di Diabetologia. Osservatorio ARNO Diabete. Rapporto 2015. Disponibile online su: https://osservatorioarno.cineca.org/journal/private/index.php?q=s&t=2&s=732 (ultimo accesso dicembre 2015)
Cegedim Patient Analyzer MAT Sett 2015. Data on file
Associazione Medici Diabetologi – AMD. Analisi prospettica degli indicatori di qualità dell’assistenza del diabete in Italia (2004-2011). Annali AMD 2012
Rosenstock J, Jelaska A, Zeller C, et al.; on behalf of the EMPA-REG BASAL trial investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17: 936-48; http://dx.doi.org/10.1111/dom.12503
Ridderstråle M, Andersen KR, Zeller C, et al.; on behalf of the EMPA-REG H2H-SU trial investigators. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691-700; http://dx.doi.org/10.1016/S2213-8587(14)70120-2
Consensus Autocontrollo. Raccomandazioni per l’autocontrollo della glicemia nel paziente diabetico. SID-AMD Rev 22/12/2012. Disponibile online su: http://www.aemmedi.it/files/Linee-guida_Raccomandazioni/2013/RACCOMANDAZIONI%20%20PER%20L’AUTOCONTROLLO-signed.pdf (ultimo accesso dicembre 2015)
Mannucci E, Torre E, Berto P. Dapagliflozin in add-on a metformina: network metanalisi e analisi di impatto di budget. Global & Regional Health Technology Assessment 2015; 2: 125-134
Schloot NC, Haupt A, Schütt M, et al.; German/Austrian DPV Initiative. Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: how big is the problem? which patients are at risk? Diabetes Metab Res Rev 2016; 32: 316-24; http://dx.doi.org/10.1002/dmrr.2722
Veronese G, Marchesini G, Forlani G, et al.; the Italian Society of Emergency Medicine (SIMEU). Costs Associated With Emergency Care and Hospitalization for Severe Hypoglycemia. Nutr Metab Cardiovasc Dis 2016; pii: S0939-4753(15)30058-2; http://dx.doi.org/10.1016/j.numecd.2016.01.007
Lombardo F, Spila Alegiani S, Maggini M, et al.; per il gruppo di Studio DAI. Prevalenza e incidenza delle complicanze del diabete: studio DAI. Istituto Superiore Di Sanità. Rapporti ISTISAN 07/25
Ministero della Salute. Analisi dei ricoveri per insufficienza cardiaca in Italia Anni 2001 – 2003. Aprile 2007. Disponibile online su: http://www.salute.gov.it/imgs/C_17_pubblicazioni_663_allegato.pdf (ultimo accesso dicembre 2015)
Held C, Gerstein HC, Yusuf S, et al.; for the ONTARGET/TRANSCEND Investigators. Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. Circulation 2007; 115: 1371-5; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.661405
Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-28; http://dx.doi.org/10.1056/NEJMoa1504720
Ministero della Salute. Ricoveri ospedalieri (SDO). Dati 2014. Disponibile online su: http://www.salute.gov.it/portale/temi/p2_4.jsp?area=ricoveriOspedalieri (ultimo accesso dicembre 2015)
Charokopou M, McEwan P, Lister S, et al. M. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective. BMC Health Serv Res 2015; 15: 496; http://dx.doi.org/10.1186/s12913-015-1139-y
Pititto L, Neslusan C, Teschemaker AR, et al. Cost-Effectiveness of Canagliflozin (Cana) Versus Sitagliptin (Sita) As Add-On To Metformin Plus Sulfonylurea In Patients With Type 2 Diabetes Mellitus (T2dm) In Brazil. Value Health 2015; 18: A864; http://dx.doi.org/10.1016/j.jval.2015.09.510
Schroeder M, Johansen P, Willis M, et al. The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (Dapa) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom. Value Health 2015; 18: A607; http://dx.doi.org/10.1016/j.jval.2015.09.2098
Charokopou M, McEwan P, Lister S, et al. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med 2015; 32: 890-8; http://dx.doi.org/10.1111/dme.12772
Abad Paniagua EJ, Casado Escribano P, Fernández Rodriguez JM, et al. Cost-effectiveness analysis of dapagliflozin compared to DPP4 inhibitors and other oral antidiabetic drugs in the treatment of type-2 diabetes mellitus in Spain. Aten Primaria 2015; 47: 505-13; http://dx.doi.org/10.1016/j.aprim.2014.11.002
Sabale U, Ekman M, Granström O, et al. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes 2015; 9: 39-47; http://dx.doi.org/10.1016/j.pcd.2014.04.007
van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig 2014; 34: 135-46; http://dx.doi.org/10.1007/s40261-013-0155-0
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
